100% - there would be so many autism spectrum disorders in pre clinical at the moment.
The one with the best results and observable clinical impact will be put into pipeline first. This is super aggressive clinical work here -> once one autism spectrum disorder is able to show benefit the rest become that much easier to get to market.
If you think of the side effects / behaviours & motor skills affected by these conditions - you would almost think trial design would be replicated. Would become cookie cutter - and after the first two or so clinical trials, there will be a fair idea of when benefit can be seen & trial length optimized as a result. This is all very exciting - will we get to see this out as neuren though? I wouldn't have thought.
NEU Price at posting:
$1.11 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)